Ülke: İrlanda
Dil: İngilizce
Kaynak: HPRA (Health Products Regulatory Authority)
AMOXICILLIN (AS TRIHYDRATE), CLAVULANIC ACID
Vetoquinol UK Limited
QJ01CR02
AMOXICILLIN (AS TRIHYDRATE), CLAVULANIC ACID
250 Milligram
Tablets
POM
Canine
Amoxicillin and enzyme inhibitor
Antibacterial
Authorised
2005-10-21
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Clavaseptin 250 mg palatable tablets for dogs 2 QUALITATIVE AND QUANTITATIVE COMPOSITION 3 PHARMACEUTICAL FORM Tablet. Beige scored tablet that can be divided into equal halves. 4 CLINICAL PARTICULARS 4.1 TARGET SPECIES Dogs. 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES In dogs: treatment or adjunctive treatment of periodontal infections caused by bacteria susceptible to amoxicillin in combination with clavulanic acid i.e. _Pasteurella _spp, _Streptococcus _spp and _Escherichia coli_. 4.3 CONTRAINDICATIONS Do not use in animals with known hypersensitivity to penicillins or other substances of the -lactam group or to any of the excipients. Do not administer to gerbils, guinea pigs, hamsters, rabbits and chinchillas. Do not administer to horses and ruminating animals. Do not use in animals with serious dysfunction of the kidneys accompanied by anuria or oliguria. Do not use in cases of known resistance to the combination of amoxicillin and clavulanic acid. 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES None. Each tablet contains: Active substances: Amoxicillin (as amoxicillin trihydrate) 200 mg Clavulanic acid (as potassium salt) 50 mg Excipients Brown iron oxide (E172) 0.475 mg For the full list of excipients, see section 6.1. HEALTH PRODUCTS REGULATORY AUTHORITY ________________________________________________________________________________________________________________________ _Date Printed 09/05/2016_ _CRN 7023487_ _page number: 1_ 4.5 SPECIAL PRECAUTIONS FOR USE Special precautions for use in animals In addition to section 4.3 contraindications: In animals with impaired liver and kidney function, the use of the product should be subject to a risk/benefit evaluation by the veterinary surgeon and the posology evaluated care Belgenin tamamını okuyun